Enoxaparin Use in Acute Kidney Injury

Definition and Assessment

The Kidney Disease: Improving Global Outcomes (KDIGO) criteria define AKI as a ≥0.3 mg/dL rise in creatinine within 48 hours or a ≥50% increase from baseline within 7 days, which is essential for determining the appropriate enoxaparin dosing in patients with acute kidney injury, with a creatinine level of 1.7 mg/dL 1, 2, 3
If the baseline creatinine is unknown, a creatinine level of 1.7 mg/dL could represent Stage 1 AKI or pre-existing chronic kidney disease, highlighting the need for careful assessment of renal function in patients with elevated creatinine levels 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend calculating creatinine clearance using the Cockcroft-Gault formula, which is a critical determinant of enoxaparin dosing in patients with renal impairment, with a creatinine level of 1.7 mg/dL 3
Monitoring of serum creatinine every 2-4 days during hospitalization is crucial, as acute kidney injury can progress, requiring further dose adjustments, and anti-Xa levels should be monitored 4 hours after the third dose, targeting 0.5-1.2 IU/mL for therapeutic anticoagulation or 0.2-0.7 IU/mL for prophylaxis, to ensure optimal enoxaparin dosing 3, 4

The use of estimated GFR (eGFR) for enoxaparin dosing is unreliable in acute kidney injury and overestimates true renal function, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, emphasizing the importance of calculating creatinine clearance using the Cockcroft-Gault formula 3
In non-steady state conditions, such as acute kidney injury, reported eGFRs cannot be used for medication dosing decisions, and creatinine clearance should be calculated using actual body weight, to ensure accurate enoxaparin dosing 3